Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Basal Insulin, Bolus Insulin, DPP-IVi, SGLT2i, Topics Jul 27 | 2018Biocon/Mylan Glargine CRL; Biocon and Merck Q2 ’18 EarningsPurchase Blast
$599
Posted in: Glucose Monitoring, Topics Jul 27 | 2018New Abbott Libre 14-Day Wear, 1-Hour Warm-up and Improved MARD ApprovedPurchase Blast
$599
Posted in: DPP-IVi, Dual/triple agonist, GLP-1RA, SGLT2i, Topics Jul 26 | 2018AZ Q2 ’18 Earnings UpdatePurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Topics Jul 26 | 2018Roche Q2 '18 Earnings UpdatePurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, DPP-IVi, Dual/triple agonist, GLP-1RA, Glucagon, Insulin Delivery, Other, SGLT2i, Topics Jul 24 | 2018LLY Dual Agonist Advances to Ph3; Q2 ’18 Earnings UpdatePurchase Blast
$599
Posted in: Glucagon, Topics Jul 23 | 2018Glucagon: Thoughts on Mylan Generic and Novel Launch TimingsPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Topics Jul 23 | 2018Roche Patch Pump CE MarkedPurchase Blast
$599
Posted in: DPP-IVi, Topics Jul 19 | 2018CARMELINA CVOT Neutral; No Mention of SuperiorityPurchase Blast
$599
Posted in: Glucose Monitoring, SGLT2i, Topics Jul 18 | 2018Novartis Discontinues LIK066 in obesity; Novartis and Abbott Q2 '18 Earnings UpdatesPurchase Blast
$599
Posted in: Bolus Insulin, Glucose Monitoring, Insulin Delivery, SGLT2i, Topics Jul 17 | 2018J&J Q2 '18 Earnings UpdatePurchase Blast
$599
Posted in: Insulin Delivery, Topics Jul 17 | 2018Thoughts on CeQur/Calibra Acquisition and T2DM Patch Pump MarketPurchase Blast
$599
Posted in: SGLT2i, Topics Jul 16 | 2018Invokana Renal Outcomes Study (CREDENCE) Stopped EarlyPurchase Blast
$599
Posted in: Bolus Insulin, Glucagon, Glucose Monitoring, Insulin Delivery, Topics Jul 13 | 2018Thoughts on Beta Bionics and Implications to Stable Glucagon, Senseonics, and FiaspPurchase Blast
$599
Posted in: SGLT2i, Topics Jul 13 | 2018Invokana CV Indication Delayed 3-Months by FDAPurchase Blast
$599
Posted in: Insulin Delivery, Topics Jul 12 | 2018Sanofi/Verily Connected Care Partner Acquired by German Device ManufacturerPurchase Blast
$599
Posted in: GLP-1RA, Topics Jul 11 | 2018Albiglutide CVOT to be Presented at EASD 2018Purchase Blast
$599
Posted in: Glucose Monitoring, Topics Jul 11 | 2018Thoughts on New Dexcom G6 T2DM Basal-Only Study (MOBILE)Purchase Blast